A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies

Status:
Not yet recruiting

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies

Phase 1/Phase 2

Ellipses Pharma